Journal article
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
- Abstract:
-
BACKGROUND: Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage are not known. METHODS: We treated 428 patients who had active rheumatoid arthritis despite methotrexate therapy with placebo or infliximab, a chimeric monoclonal antibody against TNF-alpha, in intravenous doses of 3 or 10 mg per kilogram of bod...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- New England journal of medicine
- Volume:
- 343
- Issue:
- 22
- Pages:
- 1594-1602
- Publication date:
- 2000-11-01
- DOI:
- EISSN:
-
1533-4406
- ISSN:
-
0028-4793
- Source identifiers:
-
224268
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:224268
- UUID:
-
uuid:cdbf7087-221d-4de1-815f-fac0406ebc0d
- Local pid:
- pubs:224268
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2000
If you are the owner of this record, you can report an update to it here: Report update to this record